Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia

A Body; R Wong; J Shapiro; A Jalali; SA McLachlan; S Ananda; L Lipton; P Cooray; P Gibbs; B Lee; M Lee

Journal article

Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia

A Body, R Wong, J Shapiro, A Jalali, SA McLachlan, S Ananda, L Lipton, P Cooray, P Gibbs, B Lee, M Lee

Internal Medicine Journal | WILEY | Published : 2022

DOI: 10.1111/imj.15094

Abstract

Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is highly lethal. Combination chemotherapy regimens improve overall survival (OS). Historically, only one-third of mPDAC patients in Victoria received chemotherapy. Aim: To describe current Australian chemotherapy utilisation and outcomes in patients with mPDAC using the multi-site PURPLE (Pancreatic cancer: Understanding Routine Practice and Lifting End Results) registry. Methods: PURPLE collects longitudinal data on consecutive patients with pancreatic cancer seen since January 2016. Data were collated for patients with mPDAC from six Victorian sites, and analysed descriptively. Results: Three hundred and sixty-three patients ..

View full abstract

University of Melbourne Researchers

Sue-Anne McLachlan Author

Sumitra Ananda Author

Prasad Cooray Author

Peter Gibbs Author

Grants

Funding Acknowledgements

Thanks to The Walter and Eliza Hall Institute (WEHI), the Phillip Hemstritch Foundation and Pancare for funding the PURPLE database; Julie Johns and Michael Harold at Walter and Eliza Hall Institute for data extraction; and all the clinicians and researchers involved in data collection at the treatment sites, particularly Samuel Banks, (Walter and Eliza Hall Institute), Alex Grogan (Walter and Eliza Hall Institute) and Julia Shapiro (Monash University).